Taivex announced that the latest clinical trial results of its novel anticancer drug candidate T-1101 have been accepted for poster presentation at the 2025 European Society for Medical Oncology (ESMO) Congress. As Europe’s most influential oncology congress, ESMO features highly competitive abstract selection each year. The inclusion of T-1101 underscores its innovative mechanism and clinical relevance, drawing significant attention from the international oncology community.

T-1101 is a first-in-class oral small-molecule inhibitor targeting Hec1/Nek2, specifically designed for the treatment of advanced solid tumors. By disrupting a key pathway involved in tumor cell proliferation, T-1101 offers a potential breakthrough therapeutic option for difficult-to-treat cancers. Its scientific approach aligns with ESMO’s mission to foster innovation and improve outcomes in oncology care.

The poster will present results from the Phase I clinical trial, which demonstrated favorable safety and tolerability, along with preliminary signs of clinical activity. The program has obtained approvals from both the U.S. FDA and Taiwan TFDA to proceed to Phase II clinical trials. Taivex is actively preparing for global multi-center clinical trials and collaborating with international research institutions and clinical partners to accelerate the development of T-1101 and bring new hope to patients worldwide.